...
首页> 外文期刊>Calcified tissue international. >The relationship among hypertension, antihypertensive medications, and osteoporosis: A narrative review
【24h】

The relationship among hypertension, antihypertensive medications, and osteoporosis: A narrative review

机译:高血压,降压药物和骨质疏松症之间的关系:叙事回顾

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Osteoporosis and hypertension are two frequent diseases among the aging population that share a similar etiopathology and often coexist. Moreover, treatment of hypertension affects bone mineral density and, therefore, can worsen osteoporosis. This narrative review considers the influence of the main etiologic factors that contribute to the development of hypertension and osteoporosis and examines the effect of the most often used antihypertensives on bones. A computerized literature search of relevant English publications regarding the etiology of hypertension and osteoporosis as well as the impact of antihypertensives on osteoporosis from 1996 to 2011 was completed in October 2011. The latest update in the search was performed from May to June 2012. The most relevant nongenetic factors in the etiology of osteoporosis and hypertension are low calcium intake, vitamin D and vitamin K deficiency, high consumption of sodium salt, and the effects of different forms of nitric oxide. Thiazide diuretics are the only antihypertensives that have a positive influence on bone mineral density. For other antihypertensive drugs, the data are conflicting, indicating that they may have a potentially negative or positive influence on bone mineral density and fracture risk reduction. Some studies did not find a correlation between the use of antihypertensives and bone mineral density. Due to the frequent coexistence of hypertension and osteoporosis, when selecting long-term antihypertensive therapy the potential effects of antihypertensive drugs on development, worsening, or improvement of osteoporosis should also be considered.
机译:骨质疏松症和高血压是老龄化人群中的两种常见疾病,它们具有相似的病因病理,并且经常并存。此外,高血压的治疗会影响骨矿物质密度,因此会使骨质疏松症恶化。这篇叙述性综述考虑了导致高血压和骨质疏松症发展的主要病因因素的影响,并研究了最常用的降压药对骨骼的影响。从1996年至2011年,对有关高血压和骨质疏松症的病因以及抗高血压药对骨质疏松症的影响的英语相关出版物进行了计算机检索,并于2011年10月完成。该检索的最新更新是在2012年5月至2012年6月进行的。骨质疏松症和高血压病因的相关非遗传因素包括低钙摄入,维生素D和维生素K缺乏,钠盐高消耗以及不同形式的一氧化氮的影响。噻嗪类利尿剂是唯一对骨矿物质密度具有积极影响的降压药。对于其他降压药,数据相互矛盾,表明它们可能对骨矿物质密度和降低骨折风险具有潜在的负面或正面影响。一些研究未发现抗高血压药的使用与骨矿物质密度之间的相关性。由于高血压和骨质疏松症的频繁并存,在选择长期抗高血压治疗时,还应考虑使用抗高血压药对骨质疏松症的发展,恶化或改善的潜在作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号